ABSTRACT
Acute intermittent porphyria (AIP) is an inherited disorder of heme metabolism. It can produce a variety of symptoms including abdominal pain. In Spain it is an uncommon disease and consequently may not be included in the differential diagnosis of acute abdominal pain. Two cases of AIP are reported, both of which started with recurrent abdominal pain. A brief commentary of the main topics of the disease is made with special emphasis on the importance of an early diagnosis.
Subject(s)
Abdominal Pain/etiology , Porphyria, Acute Intermittent/diagnosis , Abdominal Pain/diagnosis , Adult , Diagnosis, Differential , Female , Humans , Porphyria, Acute Intermittent/complicationsABSTRACT
A new case of acute cholestatic hepatitis in a 70-years-old woman treated with ticlopidine following stroke occurred 2 months previously is presented. The patient also presented anemia which became more severe during admission, but which was resolved following withdrawal of the drug with no involvement of the other 2 series. This is the first case reported with isolated anemia related to ticlopidine.
Subject(s)
Anemia/chemically induced , Chemical and Drug Induced Liver Injury/etiology , Cholestasis/chemically induced , Platelet Aggregation Inhibitors/adverse effects , Ticlopidine/adverse effects , Acute Disease , Aged , Cerebrovascular Disorders/drug therapy , Female , HumansABSTRACT
The relationship between donor status for antibody to hepatitis B core antigen and the occurrence of non-A, non-B posttransfusion hepatitis in the recipient was prospectively studied in 112 patients undergoing open-heart surgery who were followed for 6.5 months after surgery. Non-A, non-B posttransfusion hepatitis occurred in five (7.93%) of 63 patients who had received at least one anti-HBc-positive blood unit compared to seven (14.28%) of 49 patients who received anti-HBc-negative blood only. Statistical analysis revealed that the incidence of non-A, non-B posttransfusion hepatitis was independent of the use of blood positive for anti-HBc. Based upon these results and the high prevalence (17.3%) of anti-HBc among our blood donor population, the exclusion of anti-HBc-positive blood does not seem appropriate to achieve a reduction in the incidence of non-A, non-B posttransfusion hepatitis.
